We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $3.40, which surpassed the Zacks Consensus Estimate by 8.28%. IDEXX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.12%.
IDEXX’s Q4 Estimates
The Zacks Consensus Estimate for the company’s fourth-quarter revenues is pegged at $1.07 billion, indicating an increase of 12.2% from the year-ago figure.
The Zacks Consensus Estimate for EPS stands at $2.93, implying a rise of 11.8% from the year-ago figure.
Estimate Revision Trend Ahead of IDEXX’s Q4 Earnings
Estimates for fourth-quarter earnings have remained stable at $2.93 in the past 60 days.
Here’s a brief snapshot of the pet healthcare innovator’s performance leading up to this announcement.
Key Drivers of IDEXX’s Q4 Performance
Companion Animal Group (“CAG”)
The business is likely to have sustained its momentum in the fourth quarter of 2025, supported by continued commercial execution. CAG Diagnostics' recurring revenues are expected to have been a key driver of this performance, with robust gains across both the U.S. and international regions. IDEXX VetLab consumables may have benefited from higher test volumes, reflecting increased testing across major regions, including the benefits from an active installed base of premium instruments and a broader test menu. Higher realized prices are also likely to have contributed.
In the fourth quarter, IDEXX’s key innovations may have witnessed strong adoption, including the new IDEXX inVue Dx Analyzer, IDEXX Cancer Dx panel, as well as an expanded Catalyst menu, which includes the Catalyst Cortisol Test. Within Veterinary Software, Services and Diagnostic Imaging Systems, increased recurring revenues may have been led by higher realized prices, and higher subscription and support services volume from the expanded SaaS installed base. IDEXX is also likely to have witnessed continued strong growth of diagnostic imaging system placements in the fourth quarter.
However, ongoing macroeconomic and sector headwinds are likely to have continued to pressure U.S. same-store clinical visits, restricting the full extent of CAG Diagnostics’ growth. Rapid assay results may have also remained a drag, with the ongoing customer migration of pancreatic lipase testing to the Catalyst instrument platform. Management earlier anticipated this to be a 6% headwind for the third-quarter revenue growth.
Going by the Zacks Consensus Estimate, CAG’s business revenues are expected to increase 12.7% year over year in the fourth quarter of 2025.
Water
The segment’s revenues in the fourth quarter are expected to have benefited from higher realized prices and volumes. Similar to the previous quarter, both the United States and international regions are likely to have delivered a strong performance.
The Zacks Consensus Estimate for Water’s revenues implies 7.8% year-over-year growth.
Livestock, Poultry and Dairy (“LPD”)
Revenues in this division may have gained from an increase in test volumes, primarily in North America, Europe and Asia, as well as higher realized prices. We also expect stronger LPD performance across all regions.
The Zacks Consensus Estimate for LPD revenues indicates a 7.8% year-over-year increase in the fourth quarter of 2025.
What Our Model Says About IDXX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: IDEXX Laboratories has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Veracyte (VCYT - Free Report) has an Earnings ESP of +7.98% and a Zacks Rank #1. The company is expected to release fourth-quarter 2025 results soon.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.12%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS is expected to increase 13.9% from the year-ago quarter figure.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.73% and a Zacks Rank #2. The company is slated to release second-quarter fiscal 2026 results on Feb. 5.
CAH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 9.36%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS is expected to surge 20.7% from the year-ago reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +2.09% and a Zacks Rank #2. The company is slated to release fourth-quarter 2025 results on Feb. 24.
MMSI’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.1%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS is anticipated to increase 3.2% from the year-ago quarter’s figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How IDEXX Laboratories Is Placed Ahead of Q4 Earnings
Key Takeaways
IDEXX Laboratories, Inc. (IDXX - Free Report) is set to release fourth-quarter 2025 results on Feb.2, before the opening bell.
In the last reported quarter, the company posted adjusted earnings per share (EPS) of $3.40, which surpassed the Zacks Consensus Estimate by 8.28%. IDEXX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 7.12%.
IDEXX’s Q4 Estimates
The Zacks Consensus Estimate for the company’s fourth-quarter revenues is pegged at $1.07 billion, indicating an increase of 12.2% from the year-ago figure.
The Zacks Consensus Estimate for EPS stands at $2.93, implying a rise of 11.8% from the year-ago figure.
Estimate Revision Trend Ahead of IDEXX’s Q4 Earnings
Estimates for fourth-quarter earnings have remained stable at $2.93 in the past 60 days.
Here’s a brief snapshot of the pet healthcare innovator’s performance leading up to this announcement.
Key Drivers of IDEXX’s Q4 Performance
Companion Animal Group (“CAG”)
The business is likely to have sustained its momentum in the fourth quarter of 2025, supported by continued commercial execution. CAG Diagnostics' recurring revenues are expected to have been a key driver of this performance, with robust gains across both the U.S. and international regions. IDEXX VetLab consumables may have benefited from higher test volumes, reflecting increased testing across major regions, including the benefits from an active installed base of premium instruments and a broader test menu. Higher realized prices are also likely to have contributed.
In the fourth quarter, IDEXX’s key innovations may have witnessed strong adoption, including the new IDEXX inVue Dx Analyzer, IDEXX Cancer Dx panel, as well as an expanded Catalyst menu, which includes the Catalyst Cortisol Test. Within Veterinary Software, Services and Diagnostic Imaging Systems, increased recurring revenues may have been led by higher realized prices, and higher subscription and support services volume from the expanded SaaS installed base. IDEXX is also likely to have witnessed continued strong growth of diagnostic imaging system placements in the fourth quarter.
IDEXX Laboratories, Inc. Price and EPS Surprise
IDEXX Laboratories, Inc. price-eps-surprise | IDEXX Laboratories, Inc. Quote
However, ongoing macroeconomic and sector headwinds are likely to have continued to pressure U.S. same-store clinical visits, restricting the full extent of CAG Diagnostics’ growth. Rapid assay results may have also remained a drag, with the ongoing customer migration of pancreatic lipase testing to the Catalyst instrument platform. Management earlier anticipated this to be a 6% headwind for the third-quarter revenue growth.
Going by the Zacks Consensus Estimate, CAG’s business revenues are expected to increase 12.7% year over year in the fourth quarter of 2025.
Water
The segment’s revenues in the fourth quarter are expected to have benefited from higher realized prices and volumes. Similar to the previous quarter, both the United States and international regions are likely to have delivered a strong performance.
The Zacks Consensus Estimate for Water’s revenues implies 7.8% year-over-year growth.
Livestock, Poultry and Dairy (“LPD”)
Revenues in this division may have gained from an increase in test volumes, primarily in North America, Europe and Asia, as well as higher realized prices. We also expect stronger LPD performance across all regions.
The Zacks Consensus Estimate for LPD revenues indicates a 7.8% year-over-year increase in the fourth quarter of 2025.
What Our Model Says About IDXX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: IDEXX Laboratories has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks Rank #1 stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Veracyte (VCYT - Free Report) has an Earnings ESP of +7.98% and a Zacks Rank #1. The company is expected to release fourth-quarter 2025 results soon.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.12%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS is expected to increase 13.9% from the year-ago quarter figure.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.73% and a Zacks Rank #2. The company is slated to release second-quarter fiscal 2026 results on Feb. 5.
CAH’s earnings beat estimates in each of the trailing four quarters, the average surprise being 9.36%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS is expected to surge 20.7% from the year-ago reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +2.09% and a Zacks Rank #2. The company is slated to release fourth-quarter 2025 results on Feb. 24.
MMSI’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.1%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS is anticipated to increase 3.2% from the year-ago quarter’s figure.